Browse All

Current Filters

CLEAR FILTER x

TITLE

Eight-point Reliable Change on Symbol Digit Modalities Test with Ozanimod: Findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials

Author:DeLuca, John   Cohen, Jeffrey   Cree, Bruce   Comi, Giancarlo   Kappos, Ludwig   Cheng, Chun-Yen   Sheffield, James   Riolo, Jon   Thorpe, Andrew   Benedict, Ralph   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.015  

Author Institution:Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, San Francisco, CA  Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy, Milan, Italy  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Jacobs MS Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, Buffalo, NY  

Prognostic Factors of Disease Activity in Newly Diagnosed Teriflunomide-treated Patients with Multiple Sclerosis—A Nationwide Danish Study

Author:Mahler, Mie Reith   Magyari, Melinda   Pontieri, Luigi   Elberling, Frederik   Weglewski, Arkadiusz   Poulsen, Mai Bang   Bekyarov, Plamen   Illes, Zsolt   Kant, Matthias   Sejbaek, Tobias   Stilund, Morten Leif Munding   Rasmussen, Peter   Brask, Maria   Urbonaviciute, Inga   Sellebjerg, Finn   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.016  

Author Institution:Copenhagen University Hospital – Rigshospitalet, Glostrup, Denmark  Herlev-Gentofte Hospital and University of Copenhagen, Herlev, Denmark  Nordsjællands Hospital, Hillerød, Denmark  Odense University Hospital, Odense, Denmark  Sygehus Soenderjylland, Aabenraa, Denmark  Esbjerg Hospital, Esbjerg, Denmark  Goedstrup Hospital, Herning, Denmark  Aarhus University Hospital, Aarhus N, Denmark  Viborg Regional Hospital, Viborg, Denmark  Aalborg University Hospital, Aalborg, Denmark  

Depression Symptoms Moderate Link Between Infratentorial and Cervical Cord T2 Lesions on Gait Speed in Relapsing-remitting Multiple Sclerosis

Author:Bing-Canar, Hanaan   Baalbaki, Marwa   Sumowski, James   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.017  

Author Institution:Icahn School of Medicine at Mount Sinai, New York, NY  

Evaluation of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF

Author:Burton, Jodie   Youn, Saerom   Al-Ani, Abdullah   Costello, Fiona   

Session Name:P7: Multiple Sclerosis: Biomarkers, Immunology, and Basic Science  

Topic:Multiple Sclerosis  

Program Number:P7.001  

Author Institution:University of Calgary, Calgary, AB, Canada  McMaster University, Thornhill, ON, Canada  

Serum Glial Fibrillary Acidic Protein as a Predictive Marker for Developing Central Vein Sign Lesions in Radiologically Isolated Syndrome

Author:Martin, Sarah-Jane   Brand-Arzamendi, Koroboshka   Lim, Timothy   Lee, Lisa Eunyoung   Guenette, Melanie   Suthiphosuwan, Suradech   Bharatha, Aditya   Oh, Jiwon   Schneider, Raphael   

Session Name:P7: Multiple Sclerosis: Biomarkers, Immunology, and Basic Science  

Topic:Multiple Sclerosis  

Program Number:P7.002  

Author Institution:St. Michael's Hospital, Toronto, ON, Canada